{"transactions":[{"id":683711,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2026-08-18T21:25:21.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":1360544,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The pre-funded warrant has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1360544,"derivative":{"exercise_price":0.001,"exercise_date":"2026-08-16","underlying":"Common Stock","underlying_shares":1360544},"source":{"system":"sec-edgar","filing":"0001493152-26-039048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226039048/ownership.xml","form_type":"4"}},{"id":683710,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series F Warrant (Right to Buy)","published_at":"2026-08-18T21:25:21.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":170068,"ownership":{"direct":false,"nature":"By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":170068,"derivative":{"exercise_price":1.47,"underlying":"Common Stock","underlying_shares":170068},"source":{"system":"sec-edgar","filing":"0001493152-26-039048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226039048/ownership.xml","form_type":"4"}},{"id":683709,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series E Warrant (Right to Buy)","published_at":"2026-08-18T21:25:21.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":170068,"ownership":{"direct":false,"nature":"By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":170068,"derivative":{"exercise_price":1.47,"underlying":"Common Stock","underlying_shares":170068},"source":{"system":"sec-edgar","filing":"0001493152-26-039048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226039048/ownership.xml","form_type":"4"}},{"id":683708,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series F Warrant (Right to Buy)","published_at":"2026-08-18T21:25:21.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":1360544,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1360544,"derivative":{"exercise_price":1.47,"underlying":"Common Stock","underlying_shares":1360544},"source":{"system":"sec-edgar","filing":"0001493152-26-039048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226039048/ownership.xml","form_type":"4"}},{"id":683707,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series E Warrant (Right to Buy)","published_at":"2026-08-18T21:25:21.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":1360544,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1360544,"derivative":{"exercise_price":1.47,"underlying":"Common Stock","underlying_shares":1360544},"source":{"system":"sec-edgar","filing":"0001493152-26-039048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226039048/ownership.xml","form_type":"4"}},{"id":683706,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Common Stock","published_at":"2026-08-18T21:25:21.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":170068,"ownership":{"direct":false,"nature":"By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":292631,"source":{"system":"sec-edgar","filing":"0001493152-26-039048","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226039048/ownership.xml","form_type":"4"}},{"id":683716,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Series F Warrant (Right to Buy)","published_at":"2026-08-18T21:21:39.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":102040,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."}],"balance_after":102040,"derivative":{"exercise_price":1.47,"underlying":"Common Stock","underlying_shares":102040},"source":{"system":"sec-edgar","filing":"0001493152-26-039046","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315226039046/ownership.xml","form_type":"4"}},{"id":683715,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Series E Warrant (Right to Buy)","published_at":"2026-08-18T21:21:39.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":102040,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."}],"balance_after":102040,"derivative":{"exercise_price":1.47,"underlying":"Common Stock","underlying_shares":102040},"source":{"system":"sec-edgar","filing":"0001493152-26-039046","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315226039046/ownership.xml","form_type":"4"}},{"id":683714,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Common Stock","published_at":"2026-08-18T21:21:39.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":102040,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."}],"balance_after":232463,"source":{"system":"sec-edgar","filing":"0001493152-26-039046","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315226039046/ownership.xml","form_type":"4"}},{"id":736368,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T20:15:22.000Z","date":"2026-06-16","kind":"sale","planned":false,"acquired":false,"shares":11,"price":1.1901,"value":13.0911,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001493152-26-028884","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226028884/ownership.xml","form_type":"4"}},{"id":838253,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":60030,"kind":"person","name":"Bedoya-Toro Munera Maria E","position":1,"cik":"0001400048","reported_name":"Bedoya-Toro Munera Maria E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs"}}],"security":"Common Stock","published_at":"2026-03-17T21:44:21.000Z","date":"2026-02-17","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":1.27,"value":1270.0,"ownership":{"direct":true},"balance_after":1012,"source":{"system":"sec-edgar","filing":"0001493152-26-010630","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226010630/ownership.xml","form_type":"4"}},{"id":947022,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T01:00:13.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":37500,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001493152-26-000698","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226000698/ownership.xml","form_type":"4"}},{"id":947020,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T01:00:11.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":2500,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001493152-26-000699","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226000699/ownership.xml","form_type":"4"}},{"id":947021,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":60030,"kind":"person","name":"Bedoya-Toro Munera Maria E","position":1,"cik":"0001400048","reported_name":"Bedoya-Toro Munera Maria E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T01:00:10.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":9000,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001493152-26-000704","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226000704/ownership.xml","form_type":"4"}},{"id":947019,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T01:00:09.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":2500,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001493152-26-000697","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226000697/ownership.xml","form_type":"4"}},{"id":947018,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70033,"kind":"person","name":"Sandler Andrew Seth","position":1,"cik":"0001596060","reported_name":"Sandler Andrew Seth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T01:00:08.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":2500,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001493152-26-000702","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226000702/ownership.xml","form_type":"4"}},{"id":947033,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T01:00:06.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":18000,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001493152-26-000701","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315226000701/ownership.xml","form_type":"4"}},{"id":947017,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70032,"kind":"person","name":"Mento Steven J","position":1,"cik":"0001324466","reported_name":"Mento Steven J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T01:00:06.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":2500,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001493152-26-000695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226000695/ownership.xml","form_type":"4"}},{"id":947016,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70031,"kind":"person","name":"FISHER MARY","position":1,"cik":"0001272360","reported_name":"FISHER MARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T01:00:05.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":2500,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001493152-26-000700","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226000700/ownership.xml","form_type":"4"}},{"id":947015,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T01:00:05.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":2500,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001493152-26-000694","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226000694/ownership.xml","form_type":"4"}},{"id":948185,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T20:00:11.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":2500,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001493152-26-000703","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000149315226000703/ownership.xml","form_type":"4"}},{"id":947106,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70039,"kind":"person","name":"Nardo Christopher J.","position":1,"cik":"0001870247","reported_name":"Nardo Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, CDO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T20:00:08.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":18000,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001493152-26-000696","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870247/000149315226000696/ownership.xml","form_type":"4"}},{"id":958315,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Warrant (Right to Buy)","published_at":"2025-12-30T00:53:09.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":7874,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."}],"balance_after":7874,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":7874},"source":{"system":"sec-edgar","filing":"0001493152-25-029470","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315225029470/ownership.xml","form_type":"4"}},{"id":958314,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Warrant (Right to Buy)","published_at":"2025-12-30T00:53:09.000Z","date":"2025-12-23","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":7874,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."}],"balance_after":0,"derivative":{"exercise_price":12.7,"underlying":"Common Stock","underlying_shares":7874},"source":{"system":"sec-edgar","filing":"0001493152-25-029470","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315225029470/ownership.xml","form_type":"4"}},{"id":958313,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Series D Warrant (Right to Buy)","published_at":"2025-12-30T00:53:09.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":122549,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."}],"balance_after":122549,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":122549},"source":{"system":"sec-edgar","filing":"0001493152-25-029470","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315225029470/ownership.xml","form_type":"4"}},{"id":958312,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Series C Warrant (Right to Buy)","published_at":"2025-12-30T00:53:09.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":122549,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."}],"balance_after":122549,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":122549},"source":{"system":"sec-edgar","filing":"0001493152-25-029470","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315225029470/ownership.xml","form_type":"4"}},{"id":958311,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Common Stock","published_at":"2025-12-30T00:53:09.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":122549,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."}],"balance_after":130423,"source":{"system":"sec-edgar","filing":"0001493152-25-029470","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315225029470/ownership.xml","form_type":"4"}},{"id":958305,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Warrant (Right to Buy)","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":78740,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."}],"balance_after":78740,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":78740},"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":958304,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Warrant (Right to Buy)","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":78740,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."}],"balance_after":0,"derivative":{"exercise_price":12.7,"underlying":"Common Stock","underlying_shares":78740},"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":958303,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series D Warrant (Right to Buy)","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":122549,"ownership":{"direct":false,"nature":"By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":122549,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":122549},"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":958302,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series C Warrant (Right to Buy)","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":122549,"ownership":{"direct":false,"nature":"By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":122549,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":122549},"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":958301,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series D Warrant (Right to Buy)","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":490196,"ownership":{"direct":false,"nature":"By Proehl Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":490496,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":490496},"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":958300,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Series C Warrant (Right to Buy)","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":490196,"ownership":{"direct":false,"nature":"By Proehl Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":490496,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":490196},"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":958299,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Common Stock","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":122549,"ownership":{"direct":false,"nature":"By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":122563,"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":958298,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT, CHAIRMAN, CEO"}}],"security":"Common Stock","published_at":"2025-12-30T00:50:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":490196,"ownership":{"direct":false,"nature":"By Proehl Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":490255,"source":{"system":"sec-edgar","filing":"0001493152-25-029468","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225029468/ownership.xml","form_type":"4"}},{"id":1296494,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70031,"kind":"person","name":"FISHER MARY","position":1,"cik":"0001272360","reported_name":"FISHER MARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-01-23T22:04:18.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":196851,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of Common Stock and accompanying Warrant was $1.27."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."}],"balance_after":196851,"derivative":{"exercise_price":1.27,"underlying":"Common Stock","underlying_shares":196851},"source":{"system":"sec-edgar","filing":"0001654954-25-000693","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000693/section16.xml","form_type":"4"}},{"id":1296493,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70031,"kind":"person","name":"FISHER MARY","position":1,"cik":"0001272360","reported_name":"FISHER MARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-23T22:04:18.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":196851,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of Common Stock and accompanying Warrant was $1.27."}],"balance_after":196946,"source":{"system":"sec-edgar","filing":"0001654954-25-000693","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000693/section16.xml","form_type":"4"}},{"id":1296496,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"officer":true,"officer_title":"SVP, CFO"}}],"security":"Warrant (Right to Buy)","published_at":"2025-01-23T22:03:18.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":78741,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of Common Stock and accompanying Warrant was $1.27."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants issued in the private placement. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants issued in the private placement. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."}],"balance_after":78741,"derivative":{"exercise_price":1.27,"underlying":"Common Stock","underlying_shares":78741},"source":{"system":"sec-edgar","filing":"0001654954-25-000692","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000165495425000692/section16.xml","form_type":"4"}},{"id":1296495,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"officer":true,"officer_title":"SVP, CFO"}}],"security":"Common Stock","published_at":"2025-01-23T22:03:18.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":78741,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of Common Stock and accompanying Warrant was $1.27."}],"balance_after":78741,"source":{"system":"sec-edgar","filing":"0001654954-25-000692","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000165495425000692/section16.xml","form_type":"4"}},{"id":1296492,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President, CEO and Chairman"}}],"security":"Warrant (Right to Buy)","published_at":"2025-01-23T22:02:08.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":787402,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of Common Stock and accompanying Warrant was $1.27."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":787402,"derivative":{"exercise_price":1.27,"underlying":"Common Stock","underlying_shares":787402},"source":{"system":"sec-edgar","filing":"0001654954-25-000691","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000691/section16.xml","form_type":"4"}},{"id":1296491,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2025-01-23T22:02:08.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":787402,"ownership":{"direct":false,"nature":"By Proehl Investment Ventures LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of Common Stock and accompanying Warrant was $1.27."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":799508,"source":{"system":"sec-edgar","filing":"0001654954-25-000691","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000691/section16.xml","form_type":"4"}},{"id":1296688,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-01-23T17:00:43.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":78741,"ownership":{"direct":false,"nature":"By Hale BioPharma Ventures LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of Common Stock and accompanying Warrant was $1.27."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":78741,"derivative":{"exercise_price":1.27,"underlying":"Common Stock","underlying_shares":78741},"source":{"system":"sec-edgar","filing":"0001654954-25-000690","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000165495425000690/section16.xml","form_type":"4"}},{"id":1296687,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-23T17:00:43.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":78741,"ownership":{"direct":false,"nature":"By Hale BioPharma Ventures LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of Common Stock and accompanying Warrant was $1.27."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":80957,"source":{"system":"sec-edgar","filing":"0001654954-25-000690","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000165495425000690/section16.xml","form_type":"4"}},{"id":1303565,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70033,"kind":"person","name":"Sandler Andrew Seth","position":1,"cik":"0001596060","reported_name":"Sandler Andrew Seth","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-14T23:58:37.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":5000,"derivative":{"exercise_price":1.38,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-25-000414","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000414/section16.xml","form_type":"4"}},{"id":1303563,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-14T23:57:00.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":5000,"derivative":{"exercise_price":1.38,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-25-000412","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000412/section16.xml","form_type":"4"}},{"id":1303564,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":60030,"kind":"person","name":"Bedoya-Toro Munera Maria E","position":1,"cik":"0001400048","reported_name":"Bedoya-Toro Munera Maria E","relationship":{"officer":true,"officer_title":"SVP, Regulatory Affairs"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-14T23:56:51.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":8000,"derivative":{"exercise_price":1.38,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001654954-25-000411","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000411/section16.xml","form_type":"4"}},{"id":1303562,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right  to Buy)","published_at":"2025-01-14T23:56:30.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":5000,"derivative":{"exercise_price":1.38,"exercise_date":"2025-01-14","expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-25-000409","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000409/section16.xml","form_type":"4"}},{"id":1303560,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70031,"kind":"person","name":"FISHER MARY","position":1,"cik":"0001272360","reported_name":"FISHER MARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-14T23:50:57.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":5000,"derivative":{"exercise_price":1.38,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-25-000400","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000400/section16.xml","form_type":"4"}},{"id":1303569,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"officer":true,"officer_title":"SVP, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-14T23:50:42.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"(1)\tThe shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":20000,"derivative":{"exercise_price":1.38,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001654954-25-000399","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000165495425000399/section16.xml","form_type":"4"}},{"id":1303561,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-14T23:50:31.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":45000,"derivative":{"exercise_price":1.38,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001654954-25-000398","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000398/section16.xml","form_type":"4"}},{"id":1303559,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70032,"kind":"person","name":"Mento Steven J","position":1,"cik":"0001324466","reported_name":"Mento Steven J","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-14T23:50:20.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":5000,"derivative":{"exercise_price":1.38,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-25-000397","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000397/section16.xml","form_type":"4"}},{"id":1303557,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-14T23:49:55.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":5000,"derivative":{"exercise_price":1.38,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-25-000396","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000396/section16.xml","form_type":"4"}},{"id":1303632,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70039,"kind":"person","name":"Nardo Christopher J.","position":1,"cik":"0001870247","reported_name":"Nardo Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, CDO"}}],"security":"Stock Option (right  to buy)","published_at":"2025-01-14T18:57:09.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":20000,"derivative":{"exercise_price":1.38,"exercise_date":"2025-01-14","expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001654954-25-000413","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870247/000165495425000413/section16.xml","form_type":"4"}},{"id":1303845,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-14T18:56:40.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":5000,"derivative":{"exercise_price":1.38,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-25-000410","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000165495425000410/section16.xml","form_type":"4"}},{"id":1685684,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70032,"kind":"person","name":"Mento Steven J","position":1,"cik":"0001324466","reported_name":"Mento Steven J","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-06T02:04:07.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 4, 2024."}],"balance_after":10000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001654954-24-000300","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424000300/section16.xml","form_type":"4"}},{"id":1685683,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-06T02:02:58.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12-month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12-month anniversary of the grant date."}],"balance_after":125000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001654954-24-000299","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424000299/section16.xml","form_type":"4"}},{"id":1685682,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70031,"kind":"person","name":"FISHER MARY","position":1,"cik":"0001272360","reported_name":"FISHER MARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-06T02:02:21.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 4, 2024."}],"balance_after":10000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001654954-24-000298","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424000298/section16.xml","form_type":"4"}},{"id":1685681,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-06T02:01:59.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 4, 2024."}],"balance_after":10000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001654954-24-000297","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424000297/section16.xml","form_type":"4"}},{"id":1685680,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70033,"kind":"person","name":"Sandler Andrew Seth","position":1,"cik":"0001596060","reported_name":"Sandler Andrew Seth","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-06T02:01:34.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 4, 2024."}],"balance_after":10000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001654954-24-000296","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424000296/section16.xml","form_type":"4"}},{"id":1685679,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-06T02:01:15.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 4, 2024."}],"balance_after":10000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001654954-24-000294","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424000294/section16.xml","form_type":"4"}},{"id":1685678,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-06T02:00:44.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 4, 2024."}],"balance_after":10000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001654954-24-000292","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424000292/section16.xml","form_type":"4"}},{"id":1685711,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"officer":true,"officer_title":"SVP, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-06T02:00:36.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the\n12 month anniversary of the grant date."}],"balance_after":50000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001654954-24-000291","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000165495424000291/section16.xml","form_type":"4"}},{"id":1685677,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":60030,"kind":"person","name":"Bedoya-Toro Munera Maria E","position":1,"cik":"0001400048","reported_name":"Bedoya-Toro Munera Maria E","relationship":{"officer":true,"officer_title":"SVP, Regulatory Affairs"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-06T02:00:31.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12-month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12-month anniversary of the grant date."}],"balance_after":25000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001654954-24-000290","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424000290/section16.xml","form_type":"4"}},{"id":1685769,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70039,"kind":"person","name":"Nardo Christopher J.","position":1,"cik":"0001870247","reported_name":"Nardo Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, CDO"}}],"security":"Stock Option (right to buy","published_at":"2024-01-05T21:01:23.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the\n12 month anniversary of the grant date."}],"balance_after":50000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001654954-24-000295","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870247/000165495424000295/section16.xml","form_type":"4"}},{"id":1686178,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-05T21:00:57.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 4, 2024."}],"balance_after":10000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001654954-24-000293","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000165495424000293/section16.xml","form_type":"4"}},{"id":2063041,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":60030,"kind":"person","name":"Bedoya-Toro Munera Maria E","position":1,"cik":"0001400048","reported_name":"Bedoya-Toro Munera Maria E","relationship":{"officer":true,"officer_title":"SVP, Regulatory Affairs"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-05T21:06:33.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the\n12 month anniversary of the grant date."}],"balance_after":50000,"derivative":{"exercise_price":0.31,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001654954-23-000148","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423000148/section16.xml","form_type":"4"}},{"id":2063045,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"officer":true,"officer_title":"SVP, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-05T21:06:29.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":100000,"derivative":{"exercise_price":0.31,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001654954-23-000147","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000165495423000147/section16.xml","form_type":"4"}},{"id":2063120,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70039,"kind":"person","name":"Nardo Christopher J.","position":1,"cik":"0001870247","reported_name":"Nardo Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, CDO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-05T16:06:21.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":100000,"derivative":{"exercise_price":0.31,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001654954-23-000146","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870247/000165495423000146/section16.xml","form_type":"4"}},{"id":2140569,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70033,"kind":"person","name":"Sandler Andrew Seth","position":1,"cik":"0001596060","reported_name":"Sandler Andrew Seth","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-10-07T21:06:16.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":10120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 6, 2022, the Reporting Person was granted 10,120 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":24184,"source":{"system":"sec-edgar","filing":"0001654954-22-013530","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422013530/section16.xml","form_type":"4"}},{"id":2140570,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-10-07T21:06:13.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":9810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 6, 2022, the Reporting Person was granted 9,810 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":23443,"source":{"system":"sec-edgar","filing":"0001654954-22-013529","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422013529/section16.xml","form_type":"4"}},{"id":2140568,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70031,"kind":"person","name":"FISHER MARY","position":1,"cik":"0001272360","reported_name":"FISHER MARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-07T21:05:57.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":9810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 6, 2022, the Reporting Person was granted 9,810 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":23443,"source":{"system":"sec-edgar","filing":"0001654954-22-013527","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422013527/section16.xml","form_type":"4"}},{"id":2140567,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-10-07T21:05:51.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":11359,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 6, 2022, the Reporting Person was granted 11,359 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":27145,"source":{"system":"sec-edgar","filing":"0001654954-22-013526","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422013526/section16.xml","form_type":"4"}},{"id":2140566,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-10-07T21:05:45.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":20654,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 6, 2022, the Reporting Person was granted 20,654 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":62398,"source":{"system":"sec-edgar","filing":"0001654954-22-013525","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422013525/section16.xml","form_type":"4"}},{"id":2140748,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-07T17:06:06.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":30155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 6, 2022, the Reporting Person was granted 30,155 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":75720,"source":{"system":"sec-edgar","filing":"0001654954-22-013528","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000165495422013528/section16.xml","form_type":"4"}},{"id":2210011,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70033,"kind":"person","name":"Sandler Andrew Seth","position":1,"cik":"0001596060","reported_name":"Sandler Andrew Seth","relationship":{"director":true}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-07-08T20:10:26.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":8874,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 7, 2022, the Reporting Person was granted 8,874 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":14064,"source":{"system":"sec-edgar","filing":"0001654954-22-009457","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422009457/section16.xml","form_type":"4"}},{"id":2210010,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-07-08T20:10:24.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":8602,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 7, 2022, the Reporting Person was granted 8,602 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":13633,"source":{"system":"sec-edgar","filing":"0001654954-22-009456","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422009456/section16.xml","form_type":"4"}},{"id":2210009,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-07-08T20:10:11.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":9960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 7, 2022, the Reporting Person was granted 9,960 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":15786,"source":{"system":"sec-edgar","filing":"0001654954-22-009454","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422009454/section16.xml","form_type":"4"}},{"id":2210008,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-07-08T20:10:07.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":18110,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 7, 2022, the Reporting Person was granted 18,110 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":41744,"source":{"system":"sec-edgar","filing":"0001654954-22-009453","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422009453/section16.xml","form_type":"4"}},{"id":2210007,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70031,"kind":"person","name":"FISHER MARY","position":1,"cik":"0001272360","reported_name":"FISHER MARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-08T20:10:02.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":8602,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 7, 2022, the Reporting Person was granted 8,602 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":13633,"source":{"system":"sec-edgar","filing":"0001654954-22-009452","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422009452/section16.xml","form_type":"4"}},{"id":2210172,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-08T16:10:20.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":26441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 7, 2022, the Reporting Person was granted 26,441 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":45565,"source":{"system":"sec-edgar","filing":"0001654954-22-009455","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000165495422009455/section16.xml","form_type":"4"}},{"id":2210856,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70039,"kind":"person","name":"Nardo Christopher J.","position":1,"cik":"0001870247","reported_name":"Nardo Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, CDO"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-07T20:04:08.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":30000,"derivative":{"exercise_price":0.513,"expiration_date":"2032-06-30","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001654954-22-009392","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870247/000165495422009392/section16.xml","form_type":"4"}},{"id":2300467,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-08T23:26:27.000Z","date":"2022-04-07","kind":"grant","acquired":true,"shares":10593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 7, 2022, the Reporting Person was granted 10,593 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":15471,"source":{"system":"sec-edgar","filing":"0000905718-22-000572","document":"dermata_fm4apr72022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000572/dermata_fm4apr72022.xml","form_type":"4"}},{"id":2300466,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70031,"kind":"person","name":"FISHER MARY","position":1,"cik":"0001272360","reported_name":"FISHER MARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-08T23:19:33.000Z","date":"2022-04-07","kind":"grant","acquired":true,"shares":5031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 7, 2022, the Reporting Person was granted 5,031 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":5031,"source":{"system":"sec-edgar","filing":"0000905718-22-000570","document":"dermata_fm4apr72022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000570/dermata_fm4apr72022.xml","form_type":"4"}},{"id":2300465,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-08T23:17:45.000Z","date":"2022-04-07","kind":"grant","acquired":true,"shares":5826,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 7, 2022, the Reporting Person was granted 5,826 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":5826,"source":{"system":"sec-edgar","filing":"0000905718-22-000568","document":"dermata_fm4apr72022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000568/dermata_fm4apr72022.xml","form_type":"4"}},{"id":2300464,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70033,"kind":"person","name":"Sandler Andrew Seth","position":1,"cik":"0001596060","reported_name":"Sandler Andrew Seth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-04-08T23:15:06.000Z","date":"2022-04-07","kind":"grant","acquired":true,"shares":5190,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 7, 2022, the Reporting Person was granted 5,190 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":5190,"source":{"system":"sec-edgar","filing":"0000905718-22-000566","document":"dermata_fm4apr72022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000566/dermata_fm4apr72022.xml","form_type":"4"}},{"id":2300462,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-04-08T23:13:41.000Z","date":"2022-04-07","kind":"grant","acquired":true,"shares":5031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 7, 2022, the Reporting Person was granted 5,031 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":5031,"source":{"system":"sec-edgar","filing":"0000905718-22-000564","document":"dermata_fm4apr72022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000564/dermata_fm4apr72022.xml","form_type":"4"}},{"id":2300603,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-08T19:12:15.000Z","date":"2022-04-07","kind":"grant","acquired":true,"shares":15466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 7, 2022, the Reporting Person was granted 15,466 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":19124,"source":{"system":"sec-edgar","filing":"0000905718-22-000562","document":"dermata_fm4apr72022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571822000562/dermata_fm4apr72022.xml","form_type":"4"}},{"id":2435097,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to Buy)","published_at":"2022-01-14T22:10:48.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing on January 12, 2022."}],"balance_after":10000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-01-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000905718-22-000113","document":"dermata_fm4jan122022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000113/dermata_fm4jan122022.xml","form_type":"4"}},{"id":2444442,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70033,"kind":"person","name":"Sandler Andrew Seth","position":1,"cik":"0001596060","reported_name":"Sandler Andrew Seth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T00:24:51.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 3, 2022."}],"balance_after":5000,"derivative":{"exercise_price":1.88,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000905718-22-000054","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000054/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2444464,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T00:15:17.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 40% upon the 12 month anniversary of the grant date, and will vest as to 60% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":30000,"derivative":{"exercise_price":1.88,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000905718-22-000050","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000090571822000050/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2444441,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":17937,"kind":"person","name":"WIERENGA WENDELL","position":1,"cik":"0001239956","reported_name":"WIERENGA WENDELL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T00:07:27.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 3, 2022."}],"balance_after":5000,"derivative":{"exercise_price":1.88,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000905718-22-000046","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000046/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2444440,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T00:05:36.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 3, 2022."}],"balance_after":5000,"derivative":{"exercise_price":1.88,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000905718-22-000044","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000044/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2444439,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70032,"kind":"person","name":"Mento Steven J","position":1,"cik":"0001324466","reported_name":"Mento Steven J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to Buy)","published_at":"2022-01-06T00:03:42.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 3, 2022."}],"balance_after":5000,"derivative":{"exercise_price":1.88,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000905718-22-000042","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000042/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2444438,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70031,"kind":"person","name":"FISHER MARY","position":1,"cik":"0001272360","reported_name":"FISHER MARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T00:01:28.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 3, 2022."}],"balance_after":5000,"derivative":{"exercise_price":1.88,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000905718-22-000040","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000040/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2444437,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":60030,"kind":"person","name":"Bedoya-Toro Munera Maria E","position":1,"cik":"0001400048","reported_name":"Bedoya-Toro Munera Maria E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T23:59:53.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 40% upon the 12 month anniversary of the grant date, and will vest as to 60% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date"}],"balance_after":15000,"derivative":{"exercise_price":1.88,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000905718-22-000038","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000038/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2444436,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T23:58:13.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":57859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 40% upon the 12 month anniversary of the grant date, and will vest as to 60% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":57859,"derivative":{"exercise_price":1.88,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":57859},"source":{"system":"sec-edgar","filing":"0000905718-22-000036","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000036/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2444435,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T23:58:13.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":42141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 40% upon the 12 month anniversary of the grant date, and will vest as to 60% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":42141,"derivative":{"exercise_price":2.068,"expiration_date":"2027-01-02","underlying":"Common Stock","underlying_shares":42141},"source":{"system":"sec-edgar","filing":"0000905718-22-000036","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000036/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2444434,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T23:58:13.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":4517,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4517,"derivative":{"exercise_price":2.068,"exercise_date":"2022-01-03","expiration_date":"2027-01-02","underlying":"Common Stock","underlying_shares":4517},"source":{"system":"sec-edgar","filing":"0000905718-22-000036","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000036/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2444433,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T23:58:13.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":197610,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":197610,"derivative":{"exercise_price":1.88,"exercise_date":"2022-01-03","expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":197610},"source":{"system":"sec-edgar","filing":"0000905718-22-000036","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000036/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2444526,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70039,"kind":"person","name":"Nardo Christopher J.","position":1,"cik":"0001870247","reported_name":"Nardo Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Development"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T19:22:39.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 40% upon the 12 month anniversary of the grant date, and will vest as to 60% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":30000,"derivative":{"exercise_price":1.88,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000905718-22-000052","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870247/000090571822000052/dermata_fm4jan32022.xml","form_type":"4"}}],"next_cursor":"2022-01-05T19:22:39.000000Z,2444526"}